Update on HER2 testing for breast and upper gastrointestinal tract cancers. - Wikidata - wikimedia - TriplyDB

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

http://www.wikidata.org/entity/Q37886993

about

Lapatinib for metastatic breast cancer overexpressing HER2 Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Immunotherapy for gastrointestinal malignancies.Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer.Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.

P2860

Q24203605-1C8829B0-7A8D-40A9-8113-1C69974DE9A9 Q34248282-856C771D-9E8F-43FE-8375-AB5C0A7C3C40 Q35578712-8EC101B3-E49A-4814-B6EB-D512F448FFAD Q35586700-CB56A9D4-E56B-46EA-970E-0747C8C00DF3 Q36602174-39D5E905-F3E3-4E03-945C-D3666A56D12D Q36902969-0E2B93CA-5602-453A-B75D-FFDFE94CEF80 Q37126006-E09F102E-95CB-4E45-B3BD-E5A8DE8F9D72 Q37703506-31C23313-81FE-4E49-812D-7FB89AAC17C5 Q44978934-17DEC58C-4B68-45A0-9A50-ADB0C3B1B1EF Q47163678-DC9A42AB-FB55-4FE1-983F-660CCA049C13 Q53232564-518BC71C-BD02-43C4-B0F2-D18DA39A3467

P2860

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

http://www.wikidata.org/entity/Q37886993

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@en

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@nl

type

label

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@en

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@nl

prefLabel

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@en

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@nl

P1433

Q37886993-2804C58C-903B-42CF-A4EA-DA17D847CA9D

P1476

Q37886993-5BE0D976-BFD8-486E-BD3B-E03A8E587712

P2093

Q37886993-C6F2F543-368F-482A-89EE-B25CD2AD871B

P2860

Q37886993-001B8963-77E2-4969-81DF-DFE27CEAAABA

Q37886993-06236648-5A9F-4D99-BC1C-81420BF05EC9

Q37886993-0956F63F-0318-4083-8678-651834CBCA51

Q37886993-0E536571-4212-49A5-9E5A-271E8F9C3F17

Q37886993-0FAB843A-9C48-42AB-A829-5A14F50C6958

Q37886993-10D04C59-0D16-4496-8873-F1820B10B4FF

Q37886993-175E4288-4C0E-439F-A3AA-D19F9E2D186B

Q37886993-1986E376-C0FB-4A3E-9E4A-550CBDC69502

Q37886993-1BE55C38-0343-4E63-BB00-5D676C555392

Q37886993-1E557148-38EB-42B3-8FF3-99A6B3F97FDA

P304

Q37886993-CF9008C0-AB4F-4BE7-9BF5-756066BF48BD

P31

Q37886993-5D33FD7E-E7BD-497B-91CC-C8CF0A869B44

P356

Q37886993-F30548E7-8EB5-4A7A-853B-312AE0F06550

P433

Q37886993-36E2FF24-DD36-4F27-B160-E90A5395AC8F

P478

Q37886993-BF10F547-4109-419B-9CC5-89AC128A388D

P577

Q37886993-C9D9B61C-CA16-47D4-B48C-417409D6848D

P698

Q37886993-C738FF5D-86C4-4405-B198-8032EA8710F5

P356

P1433

Biomarkers in Medicine

P1476

Update on HER2 testing for breast and upper gastrointestinal tract cancers.

@en

P2093

Jeffrey S Ross

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2010

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Molecular biomarker analyses using circulating tumor cells

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

The HER-2/neu oncogene in tumors of the gastrointestinal tract.

P304

307-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/BMM.11.31

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21657840

http://www.w3.org/2001/XMLSchema#string